Three pharmaceutical enterprises are listed in the top 100 list of Chinese enterprises for sustainable development in 2019

[pharmaceutical network industry trends] on August 31, 2019 China top 500 enterprises Summit Forum was successfully held in Jinan, Shandong Province At the forum, Wang Jiming, President of China Council for Industry and Commerce for sustainable development, invited vice president of China business association and academician of Chinese Academy of engineering, announced the top 100 list of Chinese enterprises for sustainable development in 2019 Among them, in the pharmaceutical industry, Baiyunshan, Shanghai Pharmaceutical and Yunnan Baiyao were selected On the same day, the 2019 China enterprise sustainable development index report was published It is reported that the report is a "3-8-68-191" index system based on the analysis and evaluation data of China's top 500 enterprises, consisting of competitiveness, environment, society and other three dimensions, involving 68 indicators in 8 aspects such as products, governance, employees, chemistry, resources and 191 basic data Wang Jiming said that the sustainable development index project is a summary and refinement of the work of enterprise innovation, green and sustainable development that has been carried out for many years Its purpose is to study, understand and comprehensively evaluate the sustainable development level of Chinese enterprises, and help them to make green transformation and sustainable development As a major participant in the national economy, enterprises adhere to the concept of sustainable development and firmly follow the road of green transformation, which will promote the transformation and upgrading of the whole industry, and will also contribute to China's economic development and ecological improvement So, what are the specific performances of these three shortlisted pharmaceutical enterprises in enterprise innovation, green transformation and sustainable development? In this regard, the author makes a brief review Baiyun Mountain of Guangyao: green development is the core of sustainable development Baiyun Mountain of Guangyao disclosed in the 2018 social responsibility report that the company always regards green development as the core of sustainable development of the enterprise For example, we should actively reduce fossil energy consumption, promote clean and renewable energy substitution, widely adopt clean technology, and strive to reduce greenhouse gas and air pollutant emissions; continuously improve the construction of environmental management system, set up a special working group for pollution prevention and control, and rectify key issues such as gas emissions and wastewater treatment; and actively create a "green factory" At the same time, the company takes high-quality talents as the firm cornerstone of sustainable development, and has formulated a three-year training plan for "789" young cadres (2018-2021), actively introducing talents and bringing forth new ideas, and improving the post skills and overall quality of employees through education and training Baiyunshan Guangyao accelerates the adjustment of business structure and maintains the sustainable and stable development of business performance according to the development idea of "innovation and efficiency year" In the annual report of 2018, the company achieved an operating revenue of 42.234 billion yuan in 2018, a year-on-year increase of 101.55%, and doubled its revenue According to the data, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd is an enterprise mainly engaged in the wholesale of Western medicine, medical diagnosis, monitoring and treatment equipment, and chemical products Shanghai Pharmaceutical: start from many aspects to create conditions for sustainable development According to the 2018 Shanghai Pharmaceutical corporate social responsibility report, Shanghai Pharmaceutical and West China Pharmaceutical College of Sichuan University launched strategic cooperation, which will realize the integration of innovation chain and industrial chain; in 2018, Shanghai Pharmaceutical holding and GSK launched strategic cooperation on "hepudine and Werder" in non target pharmacies, to improve the accessibility of hepatitis B drugs, so as to achieve sustainable development and win-win goals In terms of achievement contribution, for example, the "Hericium erinaceus" project completed by Shanghai Pharmaceutical Co., Ltd can significantly improve the content of relevant pharmacodynamic indexes of raw materials and finished products of Hericium erinaceus tablets, improve the quality control level of raw materials and finished products, and promote the application of Hericium erinaceus industry and the sustainable development of health industry In 2018, 14 pharmaceutical manufacturers of Shanghai Pharmaceutical obtained ISO14001 environmental management system certification, laying a solid foundation for standardized production and operation and sustainable development At the same time, the company actively participates in community affairs, invests in many aspects, and constantly strengthens the positive interaction with the community, which also creates conditions for the sustainable development of the enterprise In recent years, Shanghai pharmaceutical industry has maintained a steady growth, among which the pharmaceutical industry has performed prominently, with revenue growth of more than 16% in nine consecutive quarters In 2018, Shanghai Pharmaceutical realized an operating revenue of 159.1 billion yuan, a year-on-year increase of 22%, including a year-on-year increase of 30% in pharmaceutical industry revenue Data shows that SHP is a large pharmaceutical industry group listed in Shanghai and Hong Kong The company's main business covers pharmaceutical industry, distribution and retail Yunnan Baiyao: actively pursue the purpose of "green development" In 2018, Yunnan Baiyao continued to deepen its efforts around the four core sectors of medicine operation, planting and lifting, import and export, terminal operation, actively explore the mode of "base + Baiyao + purchaser" cooperation to build a processing plant in the production area, and realize the goal of building a processing plant for traditional Chinese medicine Sustainable utilization of resources; active layout of overseas markets; building a new retail model led by "white medicine life + experience store" In the 2018 Shanghai Pharmaceutical corporate social responsibility report, the company said that the development of circular economy, the implementation of the requirements of ecological civilization construction, and the realization of green development and low-carbon development of Yunnan Baiyao are the important elements of inheriting the 100 year culture of Yunnan Baiyao and maintaining the sustainable development of Yunnan Baiyao Over the years, the company has always adhered to the tenet of "green development", constantly optimized production capacity, adhered to the concept of green and low-carbon to plan all kinds of production infrastructure construction, and formulated all kinds of production and operation plans There was no environmental pollution event in the whole year The company has won the "2018 China listed company environmental contribution award" According to the financial report data, in 2018, Yunnan Baiyao achieved an operating revenue of 26.708 billion yuan, a year-on-year increase of 9.84%; and a net profit of 3.307 billion yuan, a year-on-year increase of 5.14% According to the data, the traditional main business of Yunnan Baiyao is pharmaceutical manufacturing and sales.